FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 9, 2026
Sab Biotherapeutics, Inc. (SABS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and net income of $13.3 million. Free cash flow was -$45.7 million. As of Sep 30, 2026 it held $205.3 million in cash and investments and $4.9 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$13.27M
+138.9% vs prior year
Operating cash flow (TTM)
$-53.91M
-43.6% vs year-ago TTM
Free cash flow (TTM)
$-58.47M
EPS
$-0.79
+78.5% vs prior year
Dividend per share
None
Shares outstanding
50.95M
+448.5% vs prior year
Net cash
$200.42M
as of Sep 30, 2026
Operating margin
-3244.9%
FY 2024
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SABS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1833214
- Former names
- Big Cypress Acquisition Corp. (until Oct 22, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M |
| Diluted EPS | -$0.79 | -$3.68 | -$7.64 | — | -$0.63 |
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | -$9.0M |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $81.1M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $42.6M |
| Stockholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M |
| Cash and investments | $143.5M | $20.8M | $56.6M | $15.0M | $33.2M |
| Total debt | $6.0M | $4.4M | $4.9M | $4.6M | $6.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 4, 2026 | Apr 28, 2026 |
All 432 Sab Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.